Highland Capital Management LLC Buys Shares of 6,393 IQVIA Holdings Inc. (NYSE:IQV)

Highland Capital Management LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,393 shares of the medical research company’s stock, valued at approximately $1,256,000.

A number of other large investors have also made changes to their positions in the company. FMR LLC grew its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Impax Asset Management Group plc increased its stake in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in IQVIA by 3.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after buying an additional 39,772 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Barclays cut their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Robert W. Baird dropped their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Stock Up 1.7 %

IQV stock opened at $201.42 on Friday. The business’s 50 day simple moving average is $200.34 and its 200 day simple moving average is $220.78. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a market capitalization of $36.56 billion, a PE ratio of 26.43, a PEG ratio of 2.12 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.